ARTICLE | Company News
Eisai sales and marketing update
July 13, 2015 7:00 AM UTC
Eisai launched Lenvima lenvatinib in Japan to treat unresectable thyroid cancer. The recommended dose for the inhibitor of multiple VEGF receptor tyrosine kinases is 24 mg once daily. Eisai did not r...